正在招募
试验总结
一项首次人体研究，评估新型第二代 PRMT5 抑制剂 BAY 3713372 在 MTAP 缺失实体瘤受试者中的安全性、耐受性、药代动力学、药效学和初步临床活性。
Who can participate
Clinical trials can have restrictive criteria of who can and can’t participate, talk to your healthcare provider if you are interested in this clinical trial.